Ensign Peak Advisors
RUBY

Ensign Peak Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Ensign Peak Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,560
Closed -$58K – 2231
2022
Q1 		$58K Hold
10,560
– – ﹤0.01% 2109
2021
Q4 		$102K Buy
+10,560
New +$146K ﹤0.01% 2057

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's RUBY Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 10,560 shares — an estimated $58K sold.

Ensign Peak Advisors first reported a position in RUBY in Q4 2021 and held it in 2 quarters. The position peaked at $102K in Q4 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 10,560 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $58K.
  • Ensign Peak Advisors first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 2 quarters.
  • Ensign Peak Advisors's Rubius Therapeutics, Inc position peaked at $102K in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.